众生药业：RAY1225注射液II期临床试验均达到主要终点

Core Viewpoint - Zhongsheng Pharmaceutical (002317) announced that the RAY1225 injection's Phase II clinical trial met all primary endpoints and achieved favorable topline analysis results, indicating that the trial results are ideal and meet expectations [1] Group 1 - The RAY1225 injection is currently advancing to Phase III clinical trials for the treatment of obesity/overweight patients and patients with type 2 diabetes [1]